Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Osteosarcoma risk in rats using PTH 1-34.

Literature DB >> 11595538

Osteosarcoma risk in rats using PTH 1-34.

E K Barbehenn, P Lurie, S M Wolfe.

Abstract

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2001 PMID： 11595538 DOI： 10.1016/s1043-2760(01)00489-1

Source DB: PubMed Journal: Trends Endocrinol Metab ISSN： 1043-2760 Impact factor: 12.015

Keyword Cloud
Cited

× No keyword cloud information.

10 in total

Review 1. HMG CoA reductase inhibitors and the skeleton: a comprehensive review.

Authors: D C Bauer
Journal: Osteoporos Int Date: 2003-05-08 Impact factor: 4.507

2. Treatment for chemotherapy-induced alopecia in mice using parathyroid hormone agonists and antagonists linked to a collagen binding domain.

Authors: Ranjitha Katikaneni; Tulasi Ponnapakkam; Hirofumi Suda; Shigeru Miyata; Joshua Sakon; Osamu Matsushita; Robert C Gensure
Journal: Int J Cancer Date: 2012-01-24 Impact factor: 7.396

3. A single injection of the anabolic bone agent, parathyroid hormone-collagen binding domain (PTH-CBD), results in sustained increases in bone mineral density for up to 12 months in normal female mice.

Authors: Tulasi Ponnapakkam; Ranjitha Katikaneni; Hirofumi Suda; Shigeru Miyata; Osamu Matsushita; Joshua Sakon; Robert C Gensure
Journal: Calcif Tissue Int Date: 2012-07-18 Impact factor: 4.333

Review 4. Protecting Bone Health in Pediatric Rheumatic Diseases: Pharmacological Considerations.

Authors: Yujuan Zhang; Diana Milojevic
Journal: Paediatr Drugs Date: 2017-06 Impact factor: 3.022

Review 5. HMG-CoA reductase inhibitors in osteoporosis: do they reduce the risk of fracture?

Authors: Raymond G Schlienger; Christoph R Meier
Journal: Drugs Aging Date: 2003 Impact factor: 3.923

Review 6. Glucocorticoid-associated osteoporosis in chronic inflammatory diseases: epidemiology, mechanisms, diagnosis, and treatment.

Authors: Emily von Scheven; Kathleen Jo Corbin; Stefano Stagi; Stagi Stefano; Rolando Cimaz
Journal: Curr Osteoporos Rep Date: 2014-09 Impact factor: 5.096

Osteosarcoma risk in rats using PTH 1-34.

Review 1. HMG CoA reductase inhibitors and the skeleton: a comprehensive review.

2. Treatment for chemotherapy-induced alopecia in mice using parathyroid hormone agonists and antagonists linked to a collagen binding domain.

3. A single injection of the anabolic bone agent, parathyroid hormone-collagen binding domain (PTH-CBD), results in sustained increases in bone mineral density for up to 12 months in normal female mice.

Review 4. Protecting Bone Health in Pediatric Rheumatic Diseases: Pharmacological Considerations.

Review 5. HMG-CoA reductase inhibitors in osteoporosis: do they reduce the risk of fracture?

Review 6. Glucocorticoid-associated osteoporosis in chronic inflammatory diseases: epidemiology, mechanisms, diagnosis, and treatment.

Review 7. The best of both worlds - managing the cancer, saving the bone.

8. Osteosarcoma associated with hyperparathyroidism.

Review 9. Osteoporosis management and falls prevention in patients with haemophilia: Review of haemophilia guidelines.

10. A bone-resorption surface-targeting nanoparticle to deliver anti-miR214 for osteoporosis therapy.